{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:00:38Z","timestamp":1780308038197,"version":"3.54.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Aminoglycosides are historically considered nephrotoxic, though contemporary once-daily dosing and preferential amikacin use may reduce this risk. We evaluated the incidence and risk factors for acute kidney injury (AKI) among patients receiving amikacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study of adult inpatients treated with amikacin between July 2018 and June 2022. Exclusion criteria were treatment &amp;lt;3 or &amp;gt;10\u2005days, baseline eGFR &amp;lt;30\u2005mL\/min\/1.73\u2005m2, or insufficient renal follow-up. AKI was defined by KDIGO criteria. Charts of patients meeting AKI criteria were reviewed to assess likely aetiology. Multivariate logistic regression identified independent predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 974 courses, 608 met the inclusion criteria. Patients had a median age of 81.0\u2005years, 52.5% were female and the median baseline eGFR was 67.1\u2005mL\/min\/1.73\u2005m2. AKI occurred in 48 patients (7.9%), with KDIGO stage 2\u20133 in 14 (2.3%). Aetiologies included prerenal azotaemia (21%), shock\/sepsis (35%), urinary obstruction (17%), contrast exposure (2.1%) and other nephrotoxic medications (2.1%); in 11 patients (22.9% of patients with AKI and 1.8% of the entire cohort), no alternative cause was identified. Multivariate analysis showed independent predictors of AKI were older age, longer interval from admission to treatment and discontinuation due to an infectious indication. Baseline eGFR, daily dose and treatment duration were not associated with AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this contemporary cohort, we observed a relatively low incidence of AKI, often secondary to, or exacerbated by, other underlying causes. These findings suggest that once-daily amikacin may potentially carry a lower nephrotoxic risk than historically reported. Further studies are warranted to confirm safety in broader patient populations<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag188","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:08:25Z","timestamp":1778760505000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute kidney injury following amikacin therapy: a retrospective cohort study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5470-2208","authenticated-orcid":false,"given":"Iris","family":"Zohar","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Edith Wolfson Medical Center , Holon ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Satra-Shenes","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Neurology Department, Edith Wolfson Medical Center , Holon ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Melloul","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Satra-Shenes","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Family Medicine, Tel Aviv District, Clalit Health Services , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Pomeranz","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Edith Wolfson Medical Center , Holon ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidaa","family":"Abu Hanna","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Edith Wolfson Medical Center , Holon ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idan","family":"Zohar","sequence":"additional","affiliation":[{"name":"IBM LTD Z Software, , Givatayim ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology Laboratory, Edith Wolfson Medical Center , Holon ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"Ben David","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Infection Control Unit, Edith Wolfson Medical Center , Holon ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-3434","authenticated-orcid":false,"given":"Yasmin","family":"Maor","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Edith Wolfson Medical Center , Holon ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026060105015449900_dkag188-B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030266","article-title":"Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"10","author":"Shamsrizi","year":"2020","journal-title":"BMJ Open"},{"key":"2026060105015449900_dkag188-B2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jac\/dkm318","article-title":"Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"60","author":"Schwaber","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026060105015449900_dkag188-B3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2026060105015449900_dkag188-B4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab387","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC \u03b2-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: a pilot multicenter randomized controlled trial (MERINO-2)","volume":"8","author":"Stewart","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026060105015449900_dkag188-B5","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab013","article-title":"PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales","volume":"3","author":"Paterson","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026060105015449900_dkag188-B6","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa112","article-title":"CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales","volume":"3","author":"Rodr\u00edguez-Ba\u00f1o","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026060105015449900_dkag188-B7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jac\/dkz457","article-title":"Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae","volume":"75","author":"Zohar","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026060105015449900_dkag188-B8","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026060105015449900_dkag188-B9","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf126","article-title":"Aminoglycoside versus \u03b2-lactam treatment for urosepsis\u2014a retrospective cohort study","volume":"7","author":"Cahan","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026060105015449900_dkag188-B10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060105015449900_dkag188-B11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/ki.1988.83","article-title":"Aminoglycoside nephrotoxicity","volume":"33","author":"Humes","year":"1988","journal-title":"Kidney Int"},{"key":"2026060105015449900_dkag188-B12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0002-9343(96)80074-X","article-title":"Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients","volume":"101","author":"Koo","year":"1996","journal-title":"Am J Med"},{"issue":"Suppl A","key":"2026060105015449900_dkag188-B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/13.suppl_A.9","article-title":"Aminoglycoside toxicity\u2014a review of clinical studies published between 1975 and 1982","volume":"13","author":"Kahlmeter","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"2026060105015449900_dkag188-B14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"key":"2026060105015449900_dkag188-B15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J Pharm Pract"},{"key":"2026060105015449900_dkag188-B16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/heartjnl-2013-304588","article-title":"Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012","volume":"100","author":"Radovanovic","year":"2014","journal-title":"Heart"},{"key":"2026060105015449900_dkag188-B17","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026060105015449900_dkag188-B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2026060105015449900_dkag188-B19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060105015449900_dkag188-B20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/B978-0-323-44942-7.00039-X","article-title":"Drug-induced acute kidney injury","author":"Caires","year":"2019","journal-title":"Critical Care Nephrology"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag188\/68391674\/dkag188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag188\/68391674\/dkag188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:02:05Z","timestamp":1780304525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag188\/8694104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag188","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag188"}}